Eckert & Ziegler expands CDMO services to support radiopharma companies
Having acquired a 53,000 sq-ft property in Berlin, the company plans to set up new laboratories, production and cleanrooms
Eckert & Ziegler Strahlen- und Medizintechnik has acquired a site in Berlin from which it can expand its contract development and manufacturing services for a variety of cancer therapeutics and radio diagnostics among others.
The Berlin City Government has granted the company a 66-year lease for the industrial property, which includes 53,000 sq. ft (5,000 m2) of factory floor, located at the north eastern limit of the city.
The group said it plans to expand its services to accommodate a variety of cancer therapeutics and radio diagnostics to support companies developing new radiopharmaceuticals.
Dr Lutz Helmke, COO of Eckert & Ziegler's medical division suggested the company may, at a later date, use the site to manufacture proprietary drugs and diagnostics.
The renovation, which will include installing new laboratories, GMP production and cleanrooms, and the creation of high-tech workplaces, will cost up to €10-mm. Both the acquisition and the renovation is part of the CDMO's €100-mm global capacity expansion programme.
Production processes developed and validated in Berlin will be duplicated in the company's US and China sites so that customers can receive identical and standardised components for their radiopharmaceuticals.
The new site is expected to meet the highest energy efficiencies given its proximity to a thermal power station.
Related News
-
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance